Whitney P. Kirschbrown

Author

Roche (Switzerland)ORCID

Also Known As

Whitney Kirschbrown, Whitney P Kirschbrown, Whitney P. Kirschbrown, Whitney Paige Kirschbrown, Zamboni, William C

Publications

618

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Certara (United States)Université Paris Cité Dana-Farber Cancer Institute Roche (United Kingdom)

About

Whitney P. Kirschbrown is an author at Roche (Switzerland) specializing in oncology, cancer therapeutics, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	214
2	Pharmacology	2	2	214
3	Cancer Therapeutics	2	2	214
4	Oncology	2	2	214
5	Breast Cancer	1	1	149

Whitney P. Kirschbrown

Publications

501

Citations

H-Index

Page 1

	Year	Citations
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study Antoinette R. Tan, Seock‐Ah Im, André Mattar, The Lancet Oncology Breast OncologyOncologyPharmacologySubcutaneous InjectionBreast Cancer	2020	149
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Journal of Clinical Oncology	2021	92
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors Anthony W. Tolcher, Patricia LoRusso, Jennifer A. Arzt, Cancer Chemotherapy and Pharmacology MedicinePharmacologyAdvanced Solid TumorsPharmacotherapyAnti-cancer Agent	2015	65
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis Suresh Agarwal, Sathej Gopalakrishnan, Sven Mensing, Hematological Oncology	2019	41
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors Angelica Quartino, Hanbin Li, Whitney P. Kirschbrown, Cancer Chemotherapy and Pharmacology	2018	36
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal, The Journal of Clinical Pharmacology	2018	36
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy Naval Daver, Jacqueline S. Garcia, Brian A. Jonas, Blood	2019	33
Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study Naval Daver, Daniel A. Pollyea, Jacqueline S. Garcia, Blood	2018	25
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study Bei Wang, Rong Deng, Stefanie Hennig, Cancer Chemotherapy and Pharmacology	2021	14
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study Whitney P. Kirschbrown, Matts Kågedal, Bei Wang, Cancer Chemotherapy and Pharmacology	2019	10

Page 1